Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976521 · ClinicalTrials.gov registry record · NA
The INFUSE - Anterior Myocardial Infarction (AMI) Study
A NA study, sponsored by Atrium Medical Corporation.
- Completed
- Registry status
- NA
- Development phase
- 452
- Enrollment target
NCT00976521 is a NA study that has completed, run by Atrium Medical Corporation. The registered enrollment target is 452 participants.
The verdict
NCT00976521, a NA study, has completed, sponsored by Atrium Medical Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 452 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites. Subjects who present with anterior ST-elevation myocardial infarction (STEMI) and an occluded proximal or mid left anterior descending (LAD) with TIMI 0/1/2 flow will be eligible for randomization to one of the following arms: 1. Local infusion of abciximab following thrombus aspiration 2. Local infusion of abciximab and no thrombus aspiration 3. No local infusion and thrombus aspiration 4. No local infusion and no thrombus aspiration In addition, a cardiac magnetic resonance imaging (MRI) sub-study evaluating microvascular obstruction (MVO) will be performed with up to 160 subjects at up to 20 sites.
Interventions
- DRUG Abciximab local infusion
- OTHER No local infusion
- PROCEDURE Thrombus aspiration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00976521
The ClinicalTrials.gov registry entry for NCT00976521 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 452 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atrium Medical Corporation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Abciximab local infusion is the first listed.
NCT00976521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00976521 about?
NCT00976521 is a clinical study titled "The INFUSE - Anterior Myocardial Infarction (AMI) Study". This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites. Subjects who present with anterior ST-elevation myocardial infarction (STEMI) and an occluded proximal or mid left anterior descending (LAD) with TIMI 0/1...
What is the current status of trial NCT00976521?
This trial is currently completed. It is a NA study. The enrollment target is 452 participants. The study started on 2009-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00976521?
The interventions under investigation include: Abciximab local infusion (DRUG), No local infusion (OTHER), Thrombus aspiration (PROCEDURE).
Who is sponsoring clinical trial NCT00976521?
This trial is sponsored by Atrium Medical Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.